NCCN Guidelines® Updates: Management of Metastatic Colorectal Cancer
The approval of new therapies has substantially expanded the treatment options for metastatic colorectal cancer (mCRC) in recent years, raising new questions about how to select the most appropriate therapy for a specific patient and how to optimally sequence these therapies.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarker Testing for Immunotherapy
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Category
  • Bladder Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Kidney Cancer
  • Lung Cancers
  • Melanoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colorectal Cancer
Emerging Approaches to Personalized Medicine in Colorectal Cancer
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Clinical Updates: Metastatic Colorectal Cancer
Each of the therapies for mCRC are associated with certain toxicities, many of which differ depending on the mechanism of action; therefore, the supportive care needs of patients receiving systemic therapy for mCRC vary.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation